Zobrazeno 1 - 10
of 167
pro vyhledávání: '"Stephen P, Mulligan"'
Autor:
Yandong Shen, Luke Coyle, Ian Kerridge, William Stevenson, Christopher Arthur, Naomi McKinlay, Keith Fay, Christopher Ward, Matthew Greenwood, Oliver Giles Best, Ann Solterbeck, Alexander Guminski, Stephen Shumack, Stephen P. Mulligan
Publikováno v:
eJHaem, Vol 3, Iss 1, Pp 129-138 (2022)
Abstract Chronic lymphocytic leukaemia (CLL) is invariably accompanied by some degree of immune failure, and CLL patients have a high rate of second primary malignancy (SPM) compared to the general population. We comprehensively documented the incide
Externí odkaz:
https://doaj.org/article/bfe51b01464c452490529972a47017e0
Autor:
Narjis Fatima, Yandong Shen, Kyle Crassini, Edwin J. Iwanowicz, Henk Lang, Donald S. Karanewsky, Richard I. Christopherson, Stephen P. Mulligan, Oliver G. Best
Publikováno v:
eJHaem, Vol 2, Iss 1, Pp 81-93 (2021)
Abstract Despite advances in therapy, a significant proportion of patients with chronic lymphocytic leukemia (CLL) relapse with drug resistant disease. Novel treatment approaches are required, particularly for high risk disease. The imipridones repre
Externí odkaz:
https://doaj.org/article/0664da1a27014eaf8dc8331aa7119ac2
Publikováno v:
Australasian Journal of Dermatology. 64:291-295
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::270dd809c261edd077732b39db7e77ee
https://doi.org/10.1111/ajd.13994
https://doi.org/10.1111/ajd.13994
Autor:
Stephen P. Mulligan, Stephen Opat, Chan Y. Cheah, Bryone Kuss, Mark Hertzberg, Paula Marlton, Sarah Poplar, Andrea Puig, Marija McGeachie, Robert Weinkove, Constantine S. Tam
Publikováno v:
Leukemia & Lymphoma. 64:312-318
Ibrutinib is a small molecule inhibitor of Bruton's tyrosine kinase indicated for the treatment of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL). The Named Patient Progr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff027f2379a8b826fc932b9f913b2174
https://doi.org/10.1080/10428194.2022.2148220
https://doi.org/10.1080/10428194.2022.2148220
Autor:
Stephen P. Mulligan, Stephen Opat, Paula Marlton, Bryone Kuss, Poppy Gerungan, Andrea Puig, Marija McGeachie, Constantine S. Tam
Publikováno v:
British Journal of Haematology. 198:790-793
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33c6da38e9f2d85b714b643326186ad3
https://doi.org/10.1111/bjh.18306
https://doi.org/10.1111/bjh.18306
Autor:
Larissa Belov, Kieran J. Matic, Susannah Hallal, O. Giles Best, Stephen P. Mulligan, Richard I. Christopherson
Publikováno v:
Journal of Extracellular Vesicles, Vol 5, Iss 0, Pp 1-12 (2016)
Extracellular vesicles (EV) are membranous particles (30–1,000 nm in diameter) secreted by cells. Important biological functions have been attributed to 2 subsets of EV, the exosomes (bud from endosomal membranes) and the microvesicles (MV; bud fro
Externí odkaz:
https://doaj.org/article/e11e1da5dbbb4967b533a00eedf68edc
Autor:
Silvia Bonfiglio, Lesley-Ann Sutton, Viktor Ljungström, Antonella Capasso, Tatjana Pandzic, Simone Weström, Hassan Foroughi-Asl, Aron Skaftason, Anna Gellerbring, Anna Lyander, Francesca Gandini, Gianluca Gaidano, Livio Trentin, Lisa Bonello, Gianluigi Reda, Csaba Bödör, Niki Stavroyianni, Constantine S. Tam, Roberto Marasca, Francesco Forconi, Panayiotis Panayiotidis, Ingo Ringshausen, Ozren Jaksic, Anna Maria Frustaci, Sunil Iyengar, Marta Coscia, Stephen P. Mulligan, Loïc Ysebaert, Vladimir Strugov, Carolina Pavlovsky, Renata Walewska, Anders Österborg, Diego Cortese, Pamela Ranghetti, Panagiotis Baliakas, Kostas Stamatopoulos, Lydia Scarfò, Richard Rosenquist, Paolo Ghia
Publikováno v:
Blood Advances
Patients with chronic lymphocytic leukemia (CLL) progressing on ibrutinib constitute an unmet clinical need. Though BTK and PLCG2 mutations are associated with ibrutinib resistance, their frequency and relevance to progression are not fully understoo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad2c7ae912b770d9360cb931fa52e0de
https://hdl.handle.net/2318/1888045
https://hdl.handle.net/2318/1888045
Publikováno v:
Haematologica, Vol 103, Iss 7 (2018)
Externí odkaz:
https://doaj.org/article/c53d8c739d954f62a9844a8bff271e8e
Autor:
Yandong Shen, Jane A. Freeman, Juliette Holland, Kartik Naidu, Ann Solterbeck, Nenna Van Bilsen, Paul Downe, Ian Kerridge, Lucinda Wallman, Anouschka Akerman, Anupriya Aggarwal, Vanessa Milogiannakis, Gabriela Martins Costa Gomes, Chloe M. Doyle, Kerrie J. Sandgren, Stuart Turville, Anthony L. Cunningham, Stephen P. Mulligan
Publikováno v:
Blood. 140(25)
Patients with chronic lymphocytic leukemia (CLL) or monoclonal B-lymphocytosis (MBL) have impaired response to COVID-19 vaccination. A total of 258 patients (215 with CLL and 43 with MBL) had antispike antibody levels evaluable for statistical analys
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42f44f4a8862f4f627dd46bb26470158
https://pubmed.ncbi.nlm.nih.gov/36548017
https://pubmed.ncbi.nlm.nih.gov/36548017
Autor:
Davide Rossi, Ritsuro Suzuki, Xavier Badoux, Eduardo Cervera Ceballos, Florence Cymbalista, Alexander Egle, Virginia Abello, Hoa T. T. Tran, Peter Hillmen, Stephen P. Mulligan, Jennifer R. Brown, William G. Wierda, Stephan Stilgenbauer, Yair Herishanu, Teoman Soysal, Andy C. Rawstron, Colin P. Diong, Carsten Utoft Niemann, Shang Ju Wu, Paolo Ghia, Carolyn Owen
Publikováno v:
Wierda, W G, Rawstron, A, Cymbalista, F, Badoux, X, Rossi, D, Brown, J R, Egle, A, Abello, V, Cervera Ceballos, E, Herishanu, Y, Mulligan, S P, Niemann, C U, Diong, C P, Soysal, T, Suzuki, R, Tran, H T T, Wu, S J, Owen, C, Stilgenbauer, S, Ghia, P & Hillmen, P 2021, ' Measurable residual disease in chronic lymphocytic leukemia : expert review and consensus recommendations ', Leukemia, vol. 35, no. 11, pp. 3059-3072 . https://doi.org/10.1038/s41375-021-01241-1
Leukemia
Leukemia
Assessment of measurable residual disease (often referred to as “minimal residual disease”) has emerged as a highly sensitive indicator of disease burden during and at the end of treatment and has been correlated with time-to-event outcomes in ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::774cd7230252f45f812f53d22e909b45
https://doi.org/10.1038/s41375-021-01241-1
https://doi.org/10.1038/s41375-021-01241-1